Source: Cytori Therapeutics
Date: February 5, 2007
Summary:
Cytori Therapeutics and Hospital Gregorio Marañón in Madrid, Spain treated the first patient in Cytori's randomized clinical trial investigating the safety and feasibility of adipose-derived stem and regenerative cells as a therapy for cardiovascular disease. Patients in the study will receive their own adult stem and regenerative cells, thereby avoiding the risk of rejection or disease transmission that exists with donor stem cells and the controversy associated with embryonic stem cells. Once introduced into a patient's heart, the cells have shown preclinically to help the body improve blood supply that can restore circulation to the heart.
